Follow on Google News News By Tag * Tibet Pharmaceuticals Inc. * NASDAQ:TBET * Class Action * Lawsuit * Securities Class Action Lawsuit * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Tibet Pharmaceuticals, Inc. Investor Lawsuit Deadline on July 25A Deadline is coming up on July 25, 2012 in the lawsuit for investors in Tibet Pharmaceuticals, Inc. and NASDAQ-TBET stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Investors with a substantial investment in Tibet Pharmaceuticals, Inc. shares between December 28, 2010 and April 2, 2012,, should get active before the Deadline that is coming up on July 25, 2012, and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the complaint filed in the U.S. District Court of the Virgin Islands the plaintiff alleges on behalf of purchasers of Tibet Pharmaceuticals, Inc. between December 28, 2010 and April 2, 2012, that Tibet Pharmaceuticals, certain of its officers and directors, and underwriters violated Federal Securities Laws. Specifically, the plaintiff alleges that defendants issued between December 28, 2010 and April 2, 2012 allegedly inaccurate statements of material fact about Tibet Pharmaceuticals’ Shares of Tibet Pharmaceuticals, Inc. declined from $5.53 per share in January 2011 to as low as $0.72 per share in February 24, 2012. NASDAQ-TBET shares closed on April 2, 2012 at $1.29 per share. The next day the NASDAQ stock market announced that it had halted trading in Tibet Pharmaceuticals, Inc stock for “additional information requested.” The trading halt has rendered Tibet Pharmaceuticals stock illiquid. Those who purchased shares of Tibet Pharmaceuticals, Inc. between December 28, 2010 and April 2, 2012, have certain options and there are strict and short deadlines running. Deadline: July 25, 2012. NASDAQ-TBET stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|